The dynamics of CAR T-cell therapy in ALL in the market are anticipated to change in the coming years owing to improvements in research and development activities for efficient treatment options to be available in the market. The launch of emerging therapies such as Lasme-cel (UCART22) (Cellectis), WU-CART-007 (Wugen), CTD402 (Imviva), Obe-cel and AUTO1/22 (Autolus Therapeutics), and others is expected during the forecast period of 2025–2034.
LAS VEGAS, Aug. 12, 2026 /PRNewswire/ -- Recently published CAR T-Cell Therapy for ALL Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-cell therapy for ALL emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
CAR T-Cell Therapy for ALL Market Summary
The market size for CAR T-cell therapy for ALL was found to be
USD 3.2 billion in the 7MM in 2025.
The United States accounted for the largest CAR T-cell therapy for ALL treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The total incident cases of ALL in the 7MM were approximately
12,000 in 2025.
Leading CAR T-cell therapy for ALL companies, such as
Cellectis, Wugen, Imviva, Autolus Therapeutics, Fate Therapeutics, PeproMene Bio, and others, are developing new CAR T-cell therapy for ALL treatment drugs that can be available in the CAR T-cell therapy for ALL market in the coming years.
The promising CAR T-cell therapies for ALL in clinical trials include
Lasme-cel (UCART22), WU-CART-007, CTD402, Obe-cel, AUTO1/22, FT839, PMB-101, and others.
Discover what is the future of the CAR T-cell therapy for ALL treatment market @
Key Factors Driving the Growth of the CAR T-Cell Therapy for ALL Market
Rising Incidence of Relapsed/Refractory ALL: An increasing number of patients with relapsed or refractory ALL continues to create demand for effective treatment options. CAR T-cell therapy offers a promising alternative for patients who have limited success with conventional chemotherapy or stem cell transplantation.
Advancements in CAR T-Cell Technology: Continuous innovation in CAR design, manufacturing processes, and next-generation constructs is improving treatment efficacy, persistence, and safety. The development of allogeneic and dual-target CAR T-cell therapies is expected to further expand the market.
Superior Clinical Outcomes and Durable Responses: CAR T-cell therapies have demonstrated high complete remission rates and durable long-term responses, particularly in pediatric and young adult B-cell ALL. These encouraging clinical outcomes are driving greater physician confidence and broader adoption.
Strong Pipeline of Investigational Therapies: Numerous clinical-stage CAR T-cell candidates such as
Lasme-cel (UCART22) (Cellectis),
WU-CART-007 (Wugen),
CTD402 (Imviva),
Obe-cel and AUTO1/22 (Autolus Therapeutics),
FT839 (Fate Therapeutics),
PMB-101 (PeproMene Bio), and others are advancing through development. This robust pipeline is expected to introduce new treatment options and sustain long-term market growth.
As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, CAR-T cell therapies need more data supporting their use in earlier lines of therapy. Patients are likely to have better outcomes if they receive CAR-T cell therapy before multiple lines of chemotherapy, like those in the clinical trials that led to FDA approval. Moreover, even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, they have successfully reached the majority of the markets by considering the patient pool demand.
CAR T-Cell Therapy for ALL Market Analysis
CAR-T cell therapy has transformed the treatment landscape by offering the potential for durable, long-lasting responses with a single administration.
This approach may reduce the need for intensive salvage chemotherapy and autologous stem cell transplantation, thereby minimizing treatment-related toxicity in patients with high-risk disease. Its introduction has redefined the standard of care for individuals with primary refractory disease or those who experience an early relapse after frontline treatment.
The rapid evolution of immunotherapy has been marked by the emergence of CAR-T cell therapies, which represent a significant advancement in the management of Acute Lymphocytic Leukemia (ALL).
A major milestone was achieved in 2017 when the US FDA approved
KYMRIAH (tisagenlecleucel), the first CAR-T cell therapy indicated for ALL.
This was followed in October 2021 by the approval of
TECARTUS (brexucabtagene autoleucel) for adults aged 26 years and older with relapsed or refractory (R/R) B-cell precursor ALL.
Further progress was made in November 2024 with the FDA approval of
AUCATZYL (obecabtagene autoleucel), a CD19-directed genetically engineered autologous T-cell therapy, for adults with relapsed or refractory B-cell precursor ALL.
The CAR-T therapy pipeline continues to expand with promising investigational candidates, including
Lasme-cel (UCART22) (Cellectis),
WU-CART-007 (Wugen),
CTD402 (Imviva),
Obe-cel and AUTO1/22 (Autolus Therapeutics),
FT839 (Fate Therapeutics),
PMB-101 (PeproMene Bio), and several others.
Many of these emerging therapies have demonstrated encouraging efficacy and favorable safety profiles in early- and mid-stage clinical studies, highlighting their potential to further improve outcomes for patients with ALL.
CAR T-Cell Therapy for ALL Competitive Landscape
Some of the CAR T-cell therapies for ALL under development include
Lasme-cel (UCART22) (Cellectis),
WU-CART-007 (Wugen),
CTD402 (Imviva),
Obe-cel and AUTO1/22 (Autolus Therapeutics),
FT839 (Fate Therapeutics),
PMB-101 (PeproMene Bio), and others.
Cellectis' Lasme-cel is expected to address a significant share of the eligible market by offering several potential advantages over CD19-directed therapies, including a distinct therapeutic target, a single-dose treatment approach, off-the-shelf availability, and the ability to achieve deep minimal residual disease (MRD) responses in patients receiving third-line or later therapy.
Wugen's WU-CART-007 is an investigational allogeneic, off-the-shelf CAR-T cell therapy targeting CD7. It has been engineered with a fratricide-resistant design to overcome key manufacturing and biological challenges associated with developing CAR-T therapies for CD7-positive hematologic malignancies. In August 2025, Wugen secured USD 115 million through an equity financing round led by Fidelity Management & Research Company, with additional investments from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other prominent life sciences investors. The funding is intended to accelerate the ongoing pivotal T-RRex trial evaluating WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
The anticipated launch of these emerging therapies are poised to transform the CAR T-cell therapy for ALL market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CAR T-cell therapy for ALL market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which pipeline drugs could transform CAR T-cell therapy for ALL treatment @
CAR T-Cell Therapy for ALL Drugs
Recent Developments in the CAR T-Cell Therapy for ALL Market
In
June 2026, Cellectis announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its investigational CD22-directed allogeneic CAR-T cell therapy, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
In
April 2026, Wugen announced that the FDA has selected its investigational allogeneic CAR-T cell therapy, Sofi-cel, for participation in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. The company was invited to join the initiative, which annually selects up to nine development programs across the FDA's biologics and drug review centers.
In
April 2026, Autolus Therapeutics unveils new ROKA Real-World and pediatric data supporting obe-cel in ALL.
In
January 2026, the FDA awarded Orphan Drug Designation (ODD) to CTD402, an innovative allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).
CAR T-Cell Therapy for ALL Epidemiology Segmentation
The CAR T-cell therapy for ALL epidemiology section provides insights into the historical and current CAR T-cell therapy for ALL patient pool and forecasted trends for the leading markets. Among the type-specific cases of ALL in the EU4 and the UK, B-cell lymphoblastic leukemia cases were almost
4 times higher than cases of T-cell lymphoblastic leukemia in 2025.
The CAR T-cell therapy for ALL treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Total Incident Cases of ALL
Gender-specific Incident Cases of ALL
Age-specific Incident Cases of ALL
Subtype-specific Incident Cases of ALL
Genetic mutation-specific Incident Cases of ALL
Total Treated Cases of ALL
Scope of the
CAR T-Cell Therapy for ALL
Market Report
CAR T-Cell Therapy for ALL Patient Population Forecast
CAR T-Cell Therapy for ALL Therapeutics Market Size
CAR T-Cell Therapy for ALL Pipeline Analysis
CAR T-Cell Therapy for ALL Market Size and Trends
CAR T-Cell Therapy for ALL Market Opportunity
CAR T-Cell Therapy for ALL Market Unmet Needs
KOL's Views on CAR T-Cell Therapy for ALL
CAR T-Cell Therapy for ALL Market Access and Reimbursement
Download the report to understand the top emerging CAR T-cell therapies for ALL @
CAR T-Cell Therapy for ALL Clinical Trials
Table of Contents
Related Reports
CAR T-Cell Therapy Market
CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including
CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, and others.
CAR-T Market
CAR-T Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR-T companies, including
Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, and others.
Acute Lymphoblastic Leukemia Market
Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALL companies, including
AbbVie, Roche (Genentech), Janssen Research & Development, Pharmacyclics (an AbbVie Company), Incyte Corporation, Novartis, Jazz Pharmaceuticals, Autolus Therapeutics, Syndax Pharmaceuticals, Cellectis, ADC Therapeutics, Wugen, Servier, Allogene, Amgen, Astellas Pharma, Gilead Sciences, Syndax, Incyte, Orca Biosystems
, and others.
Acute Lymphoblastic Leukemia Clinical Trial Analysis
Acute Lymphoblastic Leukemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ALL companies, including
AbbVie, Roche (Genentech), Janssen Research & Development, Pharmacyclics (an AbbVie Company), Incyte Corporation, Novartis, Jazz Pharmaceuticals, Autolus Therapeutics, Syndax Pharmaceuticals, Cellectis, ADC Therapeutics, Wugen, Servier, Allogene, Amgen, Astellas Pharma, Gilead Sciences, Syndax, Incyte, Orca Biosystems, and others.
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us:
Shruti Thakur
[email protected]
+14699457679
SOURCE DelveInsight Business Research, LLP
21%
more press release views with
Request a Demo
